Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
<strong>Introduction<br></strong> Despite the growing evidence on efficacy, few economic evaluations have evaluated the cost-utility of Pidotimod (PDT) supplementation to decrease the probability of recurrent respiratory tract infections in children. This study aimed to determine t...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2022
|
| _version_ | 1797110699946672128 |
|---|---|
| author | Buendia Rodriguez, JA Guerrero Patiño, D Lindarte, EF |
| author_facet | Buendia Rodriguez, JA Guerrero Patiño, D Lindarte, EF |
| author_sort | Buendia Rodriguez, JA |
| collection | OXFORD |
| description | <strong>Introduction<br></strong>
Despite the growing evidence on efficacy, few economic evaluations have evaluated the cost-utility of Pidotimod (PDT) supplementation to decrease the probability of recurrent respiratory tract infections in children. This study aimed to determine the cost-utility of PDT to reduce the incidence rate of recurrent respiratory tract infections in children.
<br><strong>
Methods<br></strong>
A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of PDT in a patient aged 1–6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US<span>$</span>5180.
<br><strong>
Results<br></strong>
The base-case analysis showed that compared with placebo, PDT was associated with lower costs and higher QALYs. The expected annual cost per patient with PDT was US$797 (CI 95% US<span>$</span>794- US<span>$</span>801) and with placebo was US<span>$</span>1175 (CI 95% US<span>$</span>1169- US<span>$</span>1181). The QALYs per person estimated with PDT was 0.95 (CI 95% 0.94–0.95) and with placebo was 0.94 (CI 95% 0.94–0.94). The NMB with PDT was US<span>$</span> 4121 (CI 95% 4114–4127) and with placebo was US<span>$</span> 3710 (CI 95% 3700–3720). This position of absolute dominance (PDT has lower costs and higher QALYs than placebo) of PDT it is unnecessary to estimate the incremental cost-effectiveness ratio.
<br><strong>
Conclusion<br></strong>
In conclusion our study shows that PDT is a cost-effective strategy to reduce the incidence rate of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines. |
| first_indexed | 2024-03-07T07:59:58Z |
| format | Journal article |
| id | oxford-uuid:1271ffa4-ea4a-42b9-bee2-c9999196f514 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:59:58Z |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:1271ffa4-ea4a-42b9-bee2-c9999196f5142023-09-19T10:49:50ZPodotimod in pediatric recurrent respiratory tract infections: a cost-utility analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1271ffa4-ea4a-42b9-bee2-c9999196f514EnglishSymplectic ElementsBioMed Central2022Buendia Rodriguez, JAGuerrero Patiño, DLindarte, EF<strong>Introduction<br></strong> Despite the growing evidence on efficacy, few economic evaluations have evaluated the cost-utility of Pidotimod (PDT) supplementation to decrease the probability of recurrent respiratory tract infections in children. This study aimed to determine the cost-utility of PDT to reduce the incidence rate of recurrent respiratory tract infections in children. <br><strong> Methods<br></strong> A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of PDT in a patient aged 1–6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US<span>$</span>5180. <br><strong> Results<br></strong> The base-case analysis showed that compared with placebo, PDT was associated with lower costs and higher QALYs. The expected annual cost per patient with PDT was US$797 (CI 95% US<span>$</span>794- US<span>$</span>801) and with placebo was US<span>$</span>1175 (CI 95% US<span>$</span>1169- US<span>$</span>1181). The QALYs per person estimated with PDT was 0.95 (CI 95% 0.94–0.95) and with placebo was 0.94 (CI 95% 0.94–0.94). The NMB with PDT was US<span>$</span> 4121 (CI 95% 4114–4127) and with placebo was US<span>$</span> 3710 (CI 95% 3700–3720). This position of absolute dominance (PDT has lower costs and higher QALYs than placebo) of PDT it is unnecessary to estimate the incremental cost-effectiveness ratio. <br><strong> Conclusion<br></strong> In conclusion our study shows that PDT is a cost-effective strategy to reduce the incidence rate of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines. |
| spellingShingle | Buendia Rodriguez, JA Guerrero Patiño, D Lindarte, EF Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title | Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full | Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_fullStr | Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full_unstemmed | Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_short | Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_sort | podotimod in pediatric recurrent respiratory tract infections a cost utility analysis |
| work_keys_str_mv | AT buendiarodriguezja podotimodinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis AT guerreropatinod podotimodinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis AT lindarteef podotimodinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis |